Trius Therapeutics Inc 4
4 · Trius Therapeutics Inc · Filed Sep 13, 2013
Insider Transaction Report
Form 4
Onaitis Matthew
General Counsel
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2013-09-11$5.83/sh−100,000$583,000→ 0 totalExercise: $7.67Exp: 2023-05-30→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Pursuant the terms of that certain Agreement and Plan of Merger, dated as of July 30, 2013, by and among Trius Therapeutics, Inc., Cubist Pharmaceuticals, Inc., and BRGO Corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each stock option that was outstanding and unexercised as of the Offer Acceptance Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive $13.50 per share (minus the exercise price of the option) in cash plus one CVR which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.